ArticleOncotarget2018

Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.

Emilee Senkevitch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.